TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RELIEF THERAPEUTICS Holding ( (CH:RLF) ) has shared an update.
Relief Therapeutics Holding SA announced that its shareholders have approved a business combination with NeuroX Group SA, creating a publicly listed digital neurotherapeutics company. The merger, expected to close in December 2025, will see the company renamed MindMaze Therapeutics Holding SA and the integration of NeuroX’s brain health platform with Relief’s biopharmaceutical portfolio. This strategic move is anticipated to strengthen the company’s position in the neurotherapeutics industry, with new leadership appointments and a focus on expanding their R&D pipeline for neurological conditions.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF3.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, Switzerland. It focuses on delivering innovative treatments for rare and debilitating diseases, with expertise in drug delivery systems and drug repurposing. The company has a clinical pipeline targeting unmet medical needs in rare dermatological, metabolic, and respiratory conditions, and has successfully brought several products to market through licensing and distribution partnerships.
Average Trading Volume: 38,098
Technical Sentiment Signal: Buy
Current Market Cap: CHF37.21M
For an in-depth examination of RLF stock, go to TipRanks’ Overview page.